Blue Ash Therapeutics

Gregory Flexter is Chief Executive Officer and Board Member of Blue Ash Therapeutics (BAT). He has 30 years of executive leadership experience in pharmaceuticals product development, clinical research, business development, general management and executive oversight of both domestic and international operations. Having joined BAT at its founding, he is responsible for the strategic formation, development, funding and growth of theGregory Flexter company. Prior to BAT Mr. Flexter was President, CEO and Executive Board Member of Xanodyne Pharmaceuticals. Mr. Flexter served more than five years with Shire Pharmaceuticals, where he was the Executive VP and General Manager of Shire’s North American operations. Previously he led the Neuroscience Division of Novartis. Mr. Flexter began his career with Marion Laboratories.

Kevin J. Malloy, PhD, is Chief Operating Officer and Board member of BAT, who spent 25 years with Procter and Gamble Pharmaceuticals and founded BAT in December 2008. His scientific and managerial career spans all aspects of cardiovascular drug discovery, development and management. Dr. Malloy led Kevin Malloy the Discovery Team that brought forth azimilide and was its initial Global Project Leader in early career. In › 15 years of Development he has managed more than 20 P&G Project Teams and led billion-dollar alliances in Phase II and Phase III clinical programs covering ›20,000 patient years. He is a Fellow of the American Heart Association whose academic contacts and managerial skills have earned him a leadership reputation in broad cardiovascular circles, within both the pharma industry & the academic cardiology communities.




LEAD INVESTORS

  • HealthCare Value Capital (New York)
  • CincyTech Ventures (Cincinnati)
  • Queen City Angels (Cincinnati)
  • Southern Ohio Creates Companies (Cincinnati)
  • Global Cardiovascular Innovation Center (Cleveland Clinic/Ohio Third Frontier)



SCIENTIFIC ADVISORY PANEL

  • Peter R. Kowey, MD, FACC
  • Professor of Medicine & Clinical Pharmacology
  • Thomas Jefferson University
  • Chief, Division of Cardiovascular Diseases
  • Main Line Health System/Lankenau Hospital
  • Philadelphia, PA
  • Paul Dorian, MD, MSc, FACC, FRCP(C)
  • Professor of Pharmacology
  • Director, Division of Cardiology
  • University of Toronto
  • St. Michael’s Hospital
  • Toronto, Ontario CANADA
  • Gerald V. Naccarelli, MD, FHRS, FACC
  • Bernard Trabin Chair in Cardiology
  • Chief of the Division of Cardiology
  • Pennsylvania State Univ. College of Medicine
  • Hershey, PA
  • L. Brent Mitchell, MD
  • Head, Dept of Cardiac Sciences
  • & Director Libin Cardiovascular Institute
  • University of Calgary
  • Calgary, Alberta CANADA
  • James A. Reiffel, MD
  • Professor of Clinical Medicine
  • Director, Electrocardiography Lab.
  • Columbia Univ. College of Physicians & Surgeons
  • New York, NY
  • Kenneth A. Ellenbogen, M.D.
  • Kontos Professor & Chief of Cardiology
  • Medical College of Virginia
  • Virginia Commonwealth University
  • Richmond, Virginia

BOARD MEMBERS

  • Gregory D. Flexter
  • Kevin Malloy, PhD
  • Richard D’Augustine (CincyTech; Cincinnati)
  • Thomas DesChamps (HealthCare Value Capital; NYC)
  • Stefan Antonsson (Observer; Queen City Angels, Cincinnati)



LEGAL COUNSEL

  • Keating Muething and Klekamp, PLL
  • 100 East Fourth Street
  • Suite 1400
  • Cincinnati, Ohio 45202
  • (513) 579-6400